As of March 31, 2025, cash, cash equivalents, and investments were $106.9 million, which Lexeo believes will be sufficient to fund operations into 2027. “Based on the highly encouraging clinical data shared to date, we believe LX2006 could be transformational and establish a new standard of care in FA cardiomyopathy,” said R. Nolan Townsend, CEO. “We look forward to beginning enrollment in the CLARITY-FA natural history study imminently and moving as quickly as possible to initiate a registrational study for LX2006 by early 2026. We were also proud to share the promising, early data for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy and we look forward to sharing additional clinical updates later in 2025 for this program.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- RBC sees Makary interview as potentially positive for biotech stocks
- Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
- Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc.
- Biotech Alert: Searches spiking for these stocks today